Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 47, 2012 - Issue 7
Submit an article Journal homepage
348
Views
11
CrossRef citations to date
0
Altmetric
Gastrointestinal Cancer

Clinical course of sorafenib treatment in patients with hepatocellular carcinoma

Hyun Young WooDepartment of Internal Medicine, Pusan National University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
,
Jeong HeoDepartment of Internal Medicine, Pusan National University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of KoreaCorrespondence[email protected]
,
Ki Tae YoonDepartment of Internal Medicine, Pusan National University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
,
Gwang Ha KimDepartment of Internal Medicine, Pusan National University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
,
Dae Hwan KangDepartment of Internal Medicine, Pusan National University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
,
Geun Am SongDepartment of Internal Medicine, Pusan National University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
&
Mong ChoDepartment of Internal Medicine, Pusan National University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
 show all
Pages 809-819 | Received 11 Dec 2011, Accepted 01 Apr 2012, Published online: 08 May 2012

References

  • Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533–43.
  • Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17.
  • Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006;11:790–800.
  • Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005;23:8093–108.
  • Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212–25.
  • Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006;242:151–67.
  • Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–109.
  • Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851–8.
  • Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J Hepatol 2004;41:97–103.
  • Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965–72.
  • Abou Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293–300.
  • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
  • Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim JS, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet oncol 2009;10:25–34.
  • Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme M, Bouattour M, Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010;22:1106–10.
  • Wörns MA, Weinmann A, Pfingst K, Schulte Sasse C, Messow C, Schulze Bergkamen H, Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009;43:489–95.
  • Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011;34:1193–201.
  • Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14:70–6.
  • Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949–59.
  • Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36.
  • Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–30.
  • Llovet JM, Br C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–38.
  • http://ph.bayerhealthcare.co.kr/html/images/upload/pdf/nexavar_201002.pdf.
  • Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984;53:2002–7.
  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
  • Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–81.
  • Liu J, Mittendorf T, von der Schulenburg JM. A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 2010;28:312–22.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.